Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Scandion Oncology
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Further studies will require fresh capital === Edison Investment Research's estimates see the company funded to complete the ongoing CORIST and PANTAX clinical trials. However, Edison Investment Research expects the company will need a fresh capital injection in 2023 to conduct larger studies. CORIST is an open-label study and Edison Investment Research expects potential Big Pharma partners would likely prefer to review randomised data prior to striking a deal. Edison Investment Research expects the company will require an additional Phase II (or Phase II/III) trial beyond CORIST to obtain a licensing deal targeting the major US and European markets. Edison Investment Research notes that as of 1 June 2022, the company is undergoing a rights issue (for c DKK54m), which is 80% committed.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)